ubmslateCN-logo-ubm

CN Mobile Logo

Search form

Topics:

HER2-Positive Breast Cancer

HER2-Positive Breast Cancer

The 2013 ASCO/CAP updates to HER2 testing guidelines did not result in changes to the rate of HER2 positivity among breast cancer patients.

Trastuzumab plus low-dose radiotherapy does not have a significant effect on left ventricular ejection fraction changes in HER2-positive breast cancer.

Administration of dexrazoxane along with adjuvant chemotherapy was cardioprotective in patients with HER2-positive breast cancer treated with chemotherapy followed by 1 year of trastuzumab maintenance therapy.

The ASCO-CAP guidelines for HER2 gene amplification testing leave some patients at risk for misclassification and inappropriate treatment.

A cost-effectiveness analysis found that 9 weeks of trastuzumab therapy is better than the more standard 12 months in patients with HER2-positive breast cancer, without loss of clinical efficacy.

A phase I trial found that ONT-380 had a lower incidence of certain adverse events associated with this class of agent and notable anti-tumor activity in heavily pretreated metastatic HER2-positive breast cancer patients.

Brain metastases from primary breast cancer tumors often acquire clinically actionable genetic alterations, according to a small study. About one fifth of ERBB2/HER2-negative cases switched to HER2-positivity in the brain metastases.

Pages

Subscribe to HER2-Positive Breast Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.